Implant Sciences Wins Contracts for 12 Explosives Trace Detectors to U.S. GovernmentSale Includes Both Desktop and Handheld Quantum Sniffers(TM)
WILMINGTON, MA--(Marketwire - Dec 3, 2012) - Implant Sciences Corporation ( OTCQB : IMSC ), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the sale of a combination of twelve Quantum Sniffer™ QS-B220 desktop explosives and drugs trace detectors and Quantum Sniffer QS-H150 handheld explosives trace detectors to several U.S. Government agencies. The twelve units will be deployed for both civilian and military applications in building and facility security.
"These sales are a direct result of Implant Sciences' investment in U.S. Government sales and marketing. The demonstrated performance, reliability, and ease of use of our Quantum Sniffers are attracting increased awareness and acceptance with federal procurement officials. We anticipate that we will continue to grow our share of this important market," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.
"Our Quantum Sniffers have been recognized internationally as high-performing, high-value systems by governments and corporations around the globe. We are very pleased that our efforts to build U.S. Government market share is gaining traction. Our American-made products are well-positioned to serve the needs of our federal government and it is our hope to provide our systems and superior service on a broader level for both civilian and military purposes in the U.S. and worldwide at U.S. posts," added Implant Sciences' President and CEO, Glenn D. Bolduc.
About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Quantum Sniffer™ QS-B220 Desktop Explosives & Drugs Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
ontact:
Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor
Laurel Moody
646-810-0608
Email Contact |
